12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Postmarketing study data

Biogen Idec said 1 patient receiving Tysabri who initially tested negative for anti-JCV antibodies tested positive 15 months later, which the company said indicates exposure to the JC virus at some point between the 2 tests. The patient developed progressive multifocal leukoencephalopathy (PML) 2 months after...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >